

Patient Consent

WRINKLE RELASERS

Patient Information

Date Full Name

Important information as discussed with your practitioner

Wrinkle releasers contain Botulinum Toxin Type A which works by relaxing facial muscles, thereby temporarily reducing and smoothing dynamic frown lines and wrinkles, ie, those lines caused by movement of the muscles. The London Clinic uses registered medicines approved for the indication of moderate to severe glabellar lines in adults. The use of wrinkle relaxers in other regions of the face or neck is considered 'off label' use.

Wrinkle relaxers are combined with human serum albumin, a stabiliser. Albumin is routinely used in many vaccines such as the measles, mumps and rubella vaccine, chicken pox vaccine and others. There have been no reports of any infections transmitted from the albumin. If you are allergic to eggs, please notify your clinician.

The effects of wrinkle relaxers usually occurs within 10-14 days post-injection but may be noticed in some individuals in the first 7 days. It may take up to 2 weeks for peak effect of the treatment, with the duration of effect lasting approximately 3 months. The effects may vary from patient to patient depending on the dose administered and the individual patient differences. Treatment effects are temporary.

The most frequent side effects reported after treatment of the glabellar region is a headache; the other side effects may include discomfort, burning, redness or bruising at the injection site, local muscle weakness including temporary drooping of the eyelids, double vision, dry eyes, lack of feeling and nausea or flu-like symptoms. Side effects are temporary and in the case of eyelid drooping, generally resolve spontaneously within 2-4 weeks.

Wrinkle relaxers are not recommended for pregnant or breastfeeding women. Caution should be exercised in patients taking blood thinning medication. Wrinkle relaxers must not be given to patients who have had a previous allergic reaction to Botulinum Toxin Type A or are allergic to any ingredients in wrinkle relaxers; any patient with a medical condition of a neuro-muscular type such as myasthenia gravis and certain neurological disorders; or if there is any sign of infection at the proposed injection site (such as acne).

Patient Signature

Date

Clinician Signature

Date